Reply to Poddighe

Affiliations

¹ GSK, Wavre, Belgium.
² Department of Pediatrics, National Taiwan University Children's Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

Comment

Louise Stevenson et al. J Infect Dis. 2017.

. 2017 Sep 15;216(6):783-785.

doi: 10.1093/infdis/jix365.

¹ GSK, Wavre, Belgium.
² Department of Pediatrics, National Taiwan University Children's Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

No abstract available

Comment on

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.
Huang LM, Puthanakit T, Cheng-Hsun C, Ren-Bin T, Schwarz T, Pellegrino A, Esposito S, Frenette L, McNeil S, Durando P, Rheault P, Giaquinto C, Horn M, Petry KU, Peters K, Azhar T, Hillemanns P, De Simoni S, Friel D, Pemmaraju S, Hezareh M, Thomas F, Descamps D, Folschweiller N, Struyf F. Huang LM, et al. J Infect Dis. 2017 Jun 1;215(11):1711-1719. doi: 10.1093/infdis/jix154. J Infect Dis. 2017. PMID: 28591778 Free PMC article. Clinical Trial.
2-Dose Schedule of AS04-Adjuvanted Human Papillomavirus Types 16/18 Vaccine.
Poddighe D. Poddighe D. J Infect Dis. 2017 Sep 15;216(6):782-783. doi: 10.1093/infdis/jix364. J Infect Dis. 2017. PMID: 28934441 No abstract available.

1. Angelo M-G, Taylor S, Struyf F et al. . Strategies for continuous evaluation of the benefit-risk profile of human papillomavirus-16/18-AS04-adjuvanted vaccine. Expert Rev Vaccines 2014. (c); 13:1297–306. - PubMed
1. Angelo M-G, David M-P, Zima J et al. . Pooled analysis of large and long-term safety data from the AS04-adjuvanted human papillomavirus vaccine clinical trial program. Pharmacoepidemiol Drug Saf 2014; 23:466–79. - PMC - PubMed
1. Angelo M-G, Zima J, Tavares da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for AS04-adjuvanted human papillomavirus vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014. (b); 23:456–65. - PMC - PubMed
1. Willame C, Rosillon D, Zima J et al. . Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother 2016; 12:2862–71. - PMC - PubMed
1. Dray-Spira R. Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France. Presented at: 2016 Eurogin International Mutidisciplinary Congress, Salzburg, Austria. - PubMed